Table 1.
Baseline clinical characteristics of the study participants.
| Parameters | Group A (N=25) | Group B (N=32) | P value |
|---|---|---|---|
| Sex (M/F) | 19/6 | 15/17 | 0.198 |
| Age (years) | 53.76±8.89 | 50.16±7.80 | 0.109 |
| BMI (kg/m2) | 26.46±4.60 | 24.84±3.60 | 0.142 |
| SBP (mmHg) | 125.00±7.65 | 121.47±10.23 | 0.156 |
| DBP (mmHg) | 74.24±8.74 | 70.53±7.82 | 0.097 |
| TC (mmol/L) | 4.62±0.66 | 4.32±0.63 | 0.080 |
| HDL-C (mmol/L) | 1.25±0.29 | 1.63±0.36 | <0.001 |
| LDL-C (mmol/L) | 2.80±0.53 | 2.31±0.45 | <0.001 |
| TG (mmol/L) | 3.05±0.86 | 0.73±0.28 | <0.001 |
| FBG (mmol/L) | 7.43±1.01 | 4.99±0.35 | <0.001 |
| HbA1c (%) | 6.88±0.72 | 5.46±0.33 | <0.001 |
| Hcy (μmol/L) | 17.08±4.30 | 13.78±2.78 | 0.002 |
| HsCRP (mg/L) | 2.44±1.61 | 1.23±0.69 | 0.001 |
| Drug usage within 3 months (n) | |||
| Aspirin | 9 | 0 | <0.001 |
| Metformin | 19 | 0 | <0.001 |
| Insulin secretagogue | 12 | 0 | <0.001 |
| Thiazolidinedione | 10 | 0 | <0.001 |
| Acarbose | 16 | 0 | <0.001 |
| Insulin | 5 | 0 | 0.013 |
| Atorvastatin | 25 | 0 | <0.001 |
Group A – type 2 diabetes mellitus patients with hypertriglyceridemia; Group B – control subjects; BMI – body mass index; SBP – systolic blood pressure; DBP – diastolic blood pressure; TC – total cholesterol; HDL-C – high-density lipoprotein cholesterol; LDL-C – low-density lipoprotein cholesterol; TG – triglycerides; FBG – fasting blood glucose; HbA1c – glycosylated hemoglobin; Hcy – homocysteine; hsCRP – high-sensitivity C-reactive protein.